Want to see OFIX full AI Analyst Report?
OFIX Stock Chart & Stats
$9.70
$0.29(2.65%)
At close: 4:00 PM EDT
$9.70
$0.29(2.65%)
Day’s Range― - ―
52-Week Range$8.50 - $16.99
Previous Close$11.25
Volume238.98K
Average Volume (3M)344.76K
Market Cap
$383.29M
Enterprise Value$531.38
Total Cash (Recent Filing)$103.81M
Total Debt (Recent Filing)$234.62M
Price to Earnings (P/E)―
Beta0.98
Next Earnings
Nov 11, 2026EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.54
Shares Outstanding40,732,610
10 Day Avg. Volume435,779
30 Day Avg. Volume344,765
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)1.34
Price to Sales (P/S)0.74
P/FCF Ratio-472.73
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$13.00Price Target Upside34.02% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.17
Revenue Forecast (FY)$850.96M
Bulls Say, Bears Say
Bulls Say
Improving Growth OutlookRaising 2026 sales and EBITDA guidance after 5% pro forma Q2 growth indicates improving demand and operating execution. The outlook, supported by reimbursement restoration and segment gains, provides a constructive base for revenue expansion and earnings improvement over the next several quarters.
Strong Product EconomicsAdjusted gross margin of 71.7% and positive adjusted EBITDA show that Orthofix’s products carry attractive economics while operating performance improves. The $104.4M cash balance adds flexibility to fund launches and clinical work as management pursues a more profitable growth profile.
Broadening Segment MomentumGrowth is broadening beyond one product line: Spine Fixation rose 10% and Limb Reconstruction 11%, while Biologics stabilized after prior declines. VIRATA launch plans and clinical investments in biologics can expand the portfolio and support surgeon adoption over a multi-quarter horizon.
Bears Say
Persistent UnprofitabilityDespite improving EBITDA, Orthofix remains unprofitable, with negative TTM operating profit and net margin of about -7%. Continued losses mean revenue gains have not yet translated into durable shareholder returns, leaving the turnaround dependent on further execution and margin improvement.
Inconsistent Free Cash FlowOperating cash flow has turned positive, but TTM free cash flow remains about negative $27M and has been volatile across recent years. Persistent cash burn after investment needs reduces self-funding capacity and could constrain the pace of product launches, clinical programs, or other growth initiatives.
Distributor Productivity And Concentration RiskSmaller U.S. spine distributors are underperforming, while the top 30 account for roughly 80% of Spine Fixation sales. This combination exposes growth to partner productivity and concentration, and planned partner changes may limit near-term sales while commercial quality is reset.
Orthofix Medical News
OFIX FAQ
What was Orthofix Medical’s price range in the past 12 months?
Orthofix Medical lowest stock price was $8.50 and its highest was $16.99 in the past 12 months.
What is Orthofix Medical’s market cap?
Orthofix Medical’s market cap is $383.29M.
When is Orthofix Medical’s upcoming earnings report date?
Orthofix Medical’s upcoming earnings report date is Nov 11, 2026 which is in 40 days.
How were Orthofix Medical’s earnings last quarter?
Orthofix Medical released its earnings results on Aug 05, 2026. The company reported -$0.39 earnings per share for the quarter, beating the consensus estimate of -$0.41 by $0.02.
Is Orthofix Medical overvalued?
According to Wall Street analysts Orthofix Medical’s price is currently Undervalued.
Does Orthofix Medical pay dividends?
Orthofix Medical does not currently pay dividends.
What is Orthofix Medical’s EPS estimate?
Orthofix Medical’s EPS estimate is -0.27.
How many shares outstanding does Orthofix Medical have?
Orthofix Medical has 40,732,610 shares outstanding.
What happened to Orthofix Medical’s price movement after its last earnings report?
Orthofix Medical reported an EPS of -$0.39 in its last earnings report, beating expectations of -$0.41. Following the earnings report the stock price went down -14.59%.
Which hedge fund is a major shareholder of Orthofix Medical?
Currently, no hedge funds are holding shares in OFIX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Orthofix Medical Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$13.00 (34.02% Upside)
$13.00 (34.02% Upside)
Blogger Sentiment
Bullish
OFIX Sentiment 67%
Sector Average 65%
Sector Average 65%
Hedge Fund Trend
Increased
By 82.4K Shares
Last Quarter.
Last Quarter.
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-35.77%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
4.28%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Orthofix Medical
Orthofix Medical Inc., founded in 1980 and headquartered in Lewisville, Texas, operates as a global medical technology company focusing on devices and biologics. Its reach extends across the United States, several European nations including Italy, Germany, France, and the United Kingdom, as well as Brazil and other international markets. The company's operations are divided into two main segments: Global Spine and Global Orthopedics. Within the Global Spine division, Orthofix is responsible for the development, production, and distribution of bone growth stimulators. These devices are designed to facilitate bone fusion and serve as a therapeutic intervention for fractures located outside the spine and in the limbs. This segment also creates and commercializes a range of motion preservation and fixation implant products utilized in spinal surgical procedures. Furthermore, it supplies physicians with various tissue forms and synthetic-based regenerative biologic solutions to address a wide spectrum of spinal and orthopedic conditions. The Global Orthopedics segment concentrates on the design, development, and commercialization of specialized orthopedic products. These offerings are essential for procedures involving fracture repair, the correction of deformities, and bone reconstruction. Orthofix distributes its products to a diverse clientele, including physicians, hospitals, outpatient surgery centers, and integrated health delivery systems. This is achieved through a comprehensive sales network that includes its own sales force, independent distributors, and both employed and external sales representatives. The company, previously known as Orthofix International N.V., officially changed its name to Orthofix Medical Inc. in July 2018.
OFIX Company Deck
OFIX Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call conveyed cautious optimism: multiple business segments showed tangible improvement (5% consolidated pro forma growth, strong Spine Fixation and Limb Reconstruction results, stabilization in Biologics, and restored Medicare reimbursement), management raised full-year sales and EBITDA guidance, and product launches/clinical investments provide future upside. Offsetting these positives are persistent execution risks—notably underperformance among smaller U.S. spine distributors, geographic mix and credit-loss impacts on margins, and a temporary, timing-driven European MDR-related revenue boost that will reverse in 2027 and create cash timing pressure. The company appears to be in a transition toward higher-quality, more profitable growth but remains exposed to near-term execution and timing risks.View all OFIX earnings summariesOFIX Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
$13.00
▲(34.02% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month
Ownership Overview
25.74% Insiders
12.49% Mutual Funds
9.76% Other Institutional Investors
38.26% Public Companies and
Individual Investors










